Covidien Mo99 Calendar Update

Covidien is very pleased to confirm the HFR in Petten, the Netherlands, has returned to full power, as announced today by NRG, the reactor operator (see link below). We are also happy to report we expect to receive molybdenum 99 (Mo 99) from HFR-irradiated targets early next week—sooner than originally projected—for technetium 99m (Tc 99m) generator production.

The resumption of full production by HFR will return the global Mo 99 supply chain to normal levels, helping to ensure all patients in need of this vital medical isotope will receive the diagnostic and therapeutic benefits they deserve. Covidien will continue its investments to further secure the global supply chain. Examples include the recent agreement with the Maria Research Reactor in Poland; our participation on the steering committee for the new Pallas reactor in the Netherlands; and our partnership with Babcock and Wilcox Technical Services Group, Inc. These efforts will help ensure the future stability of Mo 99 production for patients worldwide.

Throughout the global Mo 99 shortage, the careful planning and cooperation of nuclear medicine professionals around the world have proven highly beneficial to patients throughout this situation, and the collaborative efforts of the entire industry are commended. That cooperative spirit will be equally important moving forward to help ensure nuclear medicine procedures are the modality of choice when most appropriate for patients.